The Shanghai Institutes for Biological Sciences (SIBS) initial human clinical trial results indicate that T cell vaccination induces immune responses that correlate with reductions in joint swelling, tenderness, pain and disability.
Pursuant to the license agreement, in exchange for an initial payment and a running royalty on the sale of commercialized products, PharmaFrontiers receives the exclusive license and all information and data related to the SIBS’ clinical trials involving the T cell vaccine.
The US Centers for Disease Control estimates that more than two million adults in the US have rheumatoid arthritis, an autoimmune disease.
“We are very excited by this research and we believe that this therapeutic T cell vaccination approach holds great promise for patients suffering from rheumatoid arthritis,” said David McWilliams, CEO of PharmaFrontiers.